ZENECA ARIMIDEX (ANASTROZOLE) LAUNCH SET FOR MID-JANUARY; FDA APPROVES ORAL TABLET FOR POST-TAMOXIFEN TREATMENT OF ADVANCED BREAST CANCER DEC. 27
Zeneca will launch Arimidex (anastrozole) in mid-January after gaining FDA approval to market the drug Dec. 27. The 1 mg once-daily anastrozole tablets were approved nine months after the March 28 NDA submission (20-541) for treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Arimidex received a "1S" review, meaning a standard review of a drug that is substantially equivalent to existing therapies and is a new molecular entity. FDA's approval comes close on the heels of approval in the U.K., where the product was approved in September.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth